As the spotlight is turned to the cost of branded drugs in the U.S., pharmaceutical companies are under growing pressure from payers and providers to contain costs.  In their article, Are De Facto Price Controls Imminent, published on March 19, 2014 in eyeforpharma, NAI President Rita Numerof, Ph.D. and Consultant Christopher de Wolff examine the impact of recent policy decisions, and the challenges manufacturers face in making the case that their products are worth their cost.

In the article, Rita and Christopher provide insights for pharma companies on what recent changes to the healthcare marketplace means for existing pharma business models and cost structures, and on how to build the economic and clinical value case to payers and providers.